Phase 1 Single Ascending and Multiple Ascending Dose Study with LCA-0321

2025-524053-14-00 Protocol LCA-0321-01 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 2 Apr 2026 · Status Ongoing, recruiting · 1 EU/EEA countries · 3 sites · Protocol LCA-0321-01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 48
Countries 1
Sites 3

Graves Disease

Key facts

Sponsor
Lycia Therapeutics Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
2 Apr 2026 → ongoing
Decision date (initial)
2026-03-06
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Graves Disease

VersionLevelCodeTermSystem organ class
26.0 PT 10018706 Graves´ disease 10014698

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Lycia Therapeutics Inc.

Sponsor organisation
Lycia Therapeutics Inc.
Address
400 East Jamie Court Suite 200
City
South San Francisco
Postcode
94080-6229
Country
United States

Scientific contact point

Organisation
Lycia Therapeutics Inc.
Contact name
Nadia Tchao

Public contact point

Organisation
Lycia Therapeutics Inc.
Contact name
Lynne Georgopoulos

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 48 3
Rest of world 0

Investigational sites

Netherlands

3 sites · Ongoing, recruiting
CTC Netherlands B.V.
CTC, Hanzeplein 1, 9713 GZ, Groningen
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Endocrinology, Dr. Molewaterplein 40, 3015 GD, Rotterdam
Brain Research Center Den Bosch B.V.
Internal medicine/ endocrinology, Statenlaan 37, 5223 LA, 's-Hertogenbosch

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2026-04-02 2026-05-18

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-12-17 Netherlands Acceptable
2026-02-18
2026-03-06
2 NON SUBSTANTIAL MODIFICATION NSM-1 2026-03-17 Netherlands Acceptable
2026-02-18
2026-03-17